EUVIMEDEUVIMED entdecken
Crossref

Dual‐Responsive Immunomodulatory RNAi Nanoplatform for Effective Immune Checkpoint Blockade and Enhanced Cancer Immunotherapy

Yuan Cao, Zixuan Zhao, Junyue Fang, Yanan Lu, Zhuoshan Huang, Guo Wu, Qiyuan Gao, Rong Li, Lei Xu, Xiaoding Xu iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202500646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Yuan Cao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Y…. Hauptthemen laut MEDLINE: Immunotherapy, Immune Checkpoint Inhibitors, Nanoparticles, RNA Interference. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Guangdong Key Areas Research and Development Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) therapy has become the first‐line treatment for cancer patients. However, the low response rate remains a clinical pain‐point. Anti‐hyperglycemic drug metformin has shown remarkable anticancer effect with the unique characteristic of modulating tumor immune microenvironment (TIME). Therefore, combining ICB with metformin could be a promising strategy for enhanced cancer immunotherapy, which however remains challenged due to the low bioavailability and severe adverse effects of metformin. This work herein designs an amphiphilic reduction‐responsive metformin prodrug, which could complex small interfering RNA (siRNA) and then co‐assemble with an endosomal pH‐responsive PEGylated polymer to form a dual‐responsive immunomodulatory RNAi nanoplatform. Using the orthotopic and metastatic breast cancer (BCa) tumor models, this work demonstrates that this RNAi nanoplatform could silence PD‐L1 expression on BCa cells and suppress their proliferation via activating AMP‐activated protein kinase (AMPK). Moreover, this AMPK activation could suppress the secretion of tumor‐derived transforming growth factor β (TGF‐β) and interleukin 6 (IL‐6), which could enhance the maturation of dendritic cells (DCs) and activation of CD8 + T cells and impair the tumor infiltration of regulatory T cells (Tregs), myeloid‐derived suppressor cells (MDSCs), and tumor‐associated macrophages (TAMs), ultimately achieving the goal of enhanced cancer immunotherapy and significant inhibition of BCa tumor growth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyImmune Checkpoint InhibitorsNanoparticlesRNA InterferenceBreast NeoplasmsAnimalsMiceHumansFemaleCell Line, TumorMetforminB7-H1 AntigenTumor MicroenvironmentRNA, Small InterferingDendritic CellsCell Proliferation

Stichwörter der Autor:innen

RNAicancer immunotherapydual‐responsivemetformin prodrugnanoplatform

Substanzen

Immune Checkpoint InhibitorsMetforminB7-H1 AntigenRNA, Small Interfering

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, P. R. China.
  • Guangzhou Key Laboratory of Medical Nanomaterials, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, P. R. China.
  • Translational Innovation Center of Precision Immunology, Sun Yat-Sen Memorial Hospital, Foshan, 528200, P. R. China.
  • Hunan Provincial Key Laboratory of Basic and Clinical Pharmacological Research of Gastrointestinal Cancer, Institute of Pharmacy and Pharmacology, the Second Affiliated Hospital, Hengyang Medical School, University of S…

ORCID-Profile: Xiaoding Xu

Förderung

  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Guangdong Key Areas Research and Development Project
  • Guangdong S&T Program
  • Guangzhou Science and Technology Bureau
  • Natural Science Foundation of Hunan Province
  • Foundation of Hunan Provincial Key Laboratory
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Cao, Y., Zhao, Z., Fang, J., Lu, Y., Huang, Z., Wu, G., Gao, Q., Li, R., Xu, L., & Xu, X. (2025). Dual‐Responsive Immunomodulatory RNAi Nanoplatform for Effective Immune Checkpoint Blockade and Enhanced Cancer Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500646

Vancouver

Cao Y, Zhao Z, Fang J, Lu Y, Huang Z, Wu G, et al. Dual‐Responsive Immunomodulatory RNAi Nanoplatform for Effective Immune Checkpoint Blockade and Enhanced Cancer Immunotherapy. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500646

BibTeX
@article{Cao2025,
  author = {Cao, Yuan and Zhao, Zixuan and Fang, Junyue and Lu, Yanan and Huang, Zhuoshan and Wu, Guo and Gao, Qiyuan and Li, Rong and Xu, Lei and Xu, Xiaoding},
  title = {Dual‐Responsive Immunomodulatory RNAi Nanoplatform for Effective Immune Checkpoint Blockade and Enhanced Cancer Immunotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202500646}
}
Kostenlos starten →